Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roivant Sciences ( (ROIV) ) has issued an announcement.
Roivant Sciences Ltd. announced that its Phase 2 RESOLVE-Lung study of namilumab in treating chronic active pulmonary sarcoidosis failed to show any treatment benefit, leading to the discontinuation of further development. Despite the setback, the study’s data will contribute significantly to future research in sarcoidosis, highlighting the inherent risks in clinical development while underscoring Roivant’s commitment to innovation in medicine.
For a thorough assessment of ROIV stock, go to TipRanks’ Stock Analysis page.